Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P8
Near historical low
vs 5Y Ago
-129.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -33.18% |
| Q3 2025 | 221.75% |
| Q2 2025 | 22.43% |
| Q1 2025 | 72.22% |
| Q4 2024 | -62.69% |
| Q3 2024 | -3.30% |
| Q2 2024 | -0.20% |
| Q1 2024 | 0.85% |
| Q4 2023 | -0.44% |
| Q3 2023 | 3.42% |
| Q2 2023 | 10.38% |
| Q1 2023 | -12.14% |
| Q4 2022 | 3.62% |
| Q3 2022 | 16.70% |
| Q2 2022 | 22.05% |
| Q1 2022 | -9.38% |
| Q4 2021 | -3.62% |
| Q3 2021 | 6.28% |
| Q2 2021 | 12.81% |
| Q1 2021 | -14.33% |
| Q4 2020 | 0.26% |
| Q3 2020 | 19.25% |
| Q2 2020 | 33.80% |
| Q1 2020 | 34.08% |
| Q4 2019 | 28.09% |
| Q3 2019 | 24.71% |
| Q2 2019 | 26.03% |
| Q1 2019 | 39.48% |
| Q4 2018 | 42.83% |
| Q3 2018 | 21.57% |
| Q2 2018 | -1.71% |
| Q1 2018 | -20.18% |
| Q4 2017 | -2.54% |
| Q3 2017 | -1.97% |
| Q2 2017 | 55.62% |
| Q1 2017 | -20.71% |
| Q4 2016 | -29.22% |
| Q3 2016 | 7677.67% |
| Q2 2016 | -103.02% |
| Q1 2016 | -52.98% |